FY2025 Earnings Forecast for ENTA Issued By Leerink Partnrs

Key Points

• Analysts at Leerink Partners have revised their FY2025 earnings per share estimate for Enanta Pharmaceuticals to ($4.04), down from the previous estimate of ($3.97).
• The company reported Q4 earnings of ($0.85) per share, exceeding the consensus estimate of ($1.25), with revenues of $18.31 million compared to an estimate of $16.21 million.
• Several brokerages have updated their ratings, with JMP Securities raising their price target from $24.00 to $25.00 and upgrading to a "market outperform" rating.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Enanta Pharmaceuticals in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of ($4.04) for the year, down from their previous estimate of ($3.97). The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.65) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals' Q4 2025 earnings at ($1.07) EPS, FY2026 earnings at ($1.97) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($1.21) EPS.

ENTA has been the subject of a number of other research reports. HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a "buy" rating and a $20.00 price target for the company. JMP Securities raised their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 12th. Finally, Wall Street Zen raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd.

Enanta Pharmaceuticals Trading Up 3.4%

Shares of ENTA traded up $0.26 during trading hours on Thursday, reaching $8.00. The company had a trading volume of 133,410 shares, compared to its average volume of 176,188. The firm has a 50 day simple moving average of $7.40 and a 200-day simple moving average of $6.50. The company has a market capitalization of $171.04 million, a price-to-earnings ratio of -1.85 and a beta of 0.88. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $13.43.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.40. The company had revenue of $18.31 million during the quarter, compared to analysts' expectations of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Sio Capital Management LLC increased its stake in shares of Enanta Pharmaceuticals by 1.0% in the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company's stock worth $1,352,000 after buying an additional 1,770 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares during the last quarter. Invesco Ltd. increased its stake in Enanta Pharmaceuticals by 4.3% during the second quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company's stock valued at $475,000 after purchasing an additional 2,607 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 8.2% during the first quarter. American Century Companies Inc. now owns 40,004 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 3,042 shares during the period. Finally, CWM LLC boosted its holdings in shares of Enanta Pharmaceuticals by 22.1% during the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company's stock valued at $162,000 after acquiring an additional 3,879 shares during the period. Hedge funds and other institutional investors own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.